Actively Recruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Led by GlaxoSmithKline · Updated on 2026-04-22
54
Participants Needed
6
Research Sites
215 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
CONDITIONS
Official Title
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male adults with metastatic castration-resistant prostate cancer confirmed by biopsy or cytology
- Prostate cancer progression while receiving androgen deprivation therapy
- ECOG performance status of 0 or 1 indicating good functional ability
- Disease progression on androgen deprivation therapy and at least one prior androgen receptor pathway inhibitor
- Received one to two prior taxane-based chemotherapy regimens
You will not qualify if you...
- Diagnosis of small cell or neuroendocrine carcinoma of the prostate or any histology other than adenocarcinoma
- Impaired heart function or clinically significant heart disease
- Any serious medical condition such as uncontrolled infection or significant lab abnormalities
- Previous treatment with androgen receptor degrader targeted therapies
- Other protocol-specific exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
GSK Investigational Site
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
2
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
3
GSK Investigational Site
West Valley City, Utah, United States, 84119
Actively Recruiting
4
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
5
GSK Investigational Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
6
GSK Investigational Site
Tokyo, Japan, 135-8550
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here